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NCAM2 Fibronectin type-III 
domains form a rigid structure that 
binds and activates the Fibroblast 
Growth Factor Receptor
Kim Krighaar Rasmussen  1,2,3, Maria Hansen Falkesgaard2, Malene Winther2, Nikolaj 
Kulahin Roed2, Christine Louise Quistgaard2, Marie Nygaard Teisen2, Sofie Marie Edslev2, 
David Leander Petersen2, Ali Aljubouri2, Claus Christensen2, Peter Waaben Thulstrup  1,  
Leila Lo Leggio  1, Kaare Teilum3 & Peter Schledermann Walmod  2
NCAM1 and NCAM2 have ectodomains consisting of 5 Ig domains followed by 2 membrane-proximal 
FnIII domains. In this study we investigate and compare the structures and functions of these FnIII 
domains. The NCAM1 and -2 FnIII2 domains both contain a Walker A motif. In NCAM1 binding of ATP to 
this motif interferes with NCAM1 binding to FGFR. We obtained a structural model of the NCAM2 FnIII2 
domain by NMR spectroscopy, and by titration with an ATP analogue we show that the NCAM2 Walker 
A motif does not bind ATP. Small angle X-ray scattering (SAXS) data revealed that the NCAM2 FnIII1-2 
double domain exhibits a very low degree of flexibility. Moreover, recombinant NCAM2 FnIII domains 
bind FGFR in vitro, and the FnIII1-2 double domain induces neurite outgrowth in a concentration-
dependent manner through activation of FGFR. Several synthetic NCAM1-derived peptides induce 
neurite outgrowth via FGFR. Only 2 of 5 peptides derived from similar regions in NCAM2 induce neurite 
outgrowth, but the most potent of these peptides stimulates neurite outgrowth through FGFR-
dependent activation of the Ras-MAPK pathway. These results reveal that the NCAM2 FnIII domains 
form a rigid structure that binds and activates FGFR in a manner related to, but different from NCAM1.
Cell adhesion molecules (CAMs) constitute a large class of plasma membrane-anchored proteins that mediate 
attachment of cells to neighboring cells and to the surrounding extracellular matrix. Furthermore, CAMs often 
form heterophilic cis-interactions through which they can regulate intracellular signal transduction cascades and 
thereby modulate a number of processes including cellular proliferation, survival, differentiation, and migra-
tion1,2. In addition, CAMs expressed in the nervous system can regulate processes such as neurite outgrowth, 
synaptic maturation and synaptic plasticity in relation to learning and memory formation3–5.
The Neural Cell Adhesion Molecule 2 (NCAM2) is a CAM belonging to the NCAM family, which in mam-
mals also includes NCAM1. However, whereas NCAM1 was originally described already in the mid-1970s6,7 and 
has been extensively studied, NCAM2 was not cloned until the mid-1990’s8, and has only been the focus of few 
studies. In the nervous system NCAM2 is reported to be involved in the outgrowth and branching of neurites9, 
filopodia formation9, axon guidance10, synapse assembly/disassembly11, and spinal cord stem cell proliferation12.
The overall structure of NCAM2 is similar to that of NCAM1, with an ectodomain consisting of 5 N-terminal, 
membrane-distal Ig domains (denoted Ig1 to -5) followed by 2 membrane-proximal fibronectin type III domains 
(denoted FnIII1 and -2, with FnIII2 being closet to the cell membrane). The primary structures of the respective 
extracellular domains, transmembrane regions and cytoplasmic domains of NCAM1 and NCAM2 are ~36–55% 
identical, suggesting that the 2 proteins have related but not identical functions10,13–15.
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The entire ectodomain of NCAM2 has been modelled using X-ray crystal structures of overlapping regions16,17. 
The structural model shows that NCAM2 molecules homodimerize via reciprocal interactions between the Ig1-2 
domains17. Moreover, a domain swapping helps low affinity interaction to be more specific16.
The least identical region of NCAM1 and NCAM2 is the FnIII2 domain. In the NCAM1 FnIII2 domain 
ecto-ATP can bind to a Walker A motif, a phosphate-binding region present in many ATP and GTP utilizing 
proteins18, and binding of ATP at this site interferes with binding of the NCAM1 FnIII domains to the Fibroblast 
Growth Factor Receptor (FGFR). ATP thereby modulates NCAM1-FGFR-mediated intracellular signal trans-
duction and the resulting biological responses like NCAM1-mediated neurite outgrowth19. Binding of ATP to 
NCAM1 also affects NCAM1-mediated cell adhesion20. A number of synthetic peptides derived from sequences 
in the NCAM1 FnIII domains are reported to bind and activate FGFR. Most notably, a synthetic peptide, FGL, 
corresponding to the NCAM1 FnIII2 FG loop has been extensively studied. This peptide promotes e.g. neurite 
outgrowth and neuronal cell survival in vitro. Furthermore, it has multiple effects in vivo including reduction of 
inflammation, promotion of learning and memory formation, and the reduction of signs of Aβ-induced neuro-
pathology and cognitive impairment in an Alzheimer’s disease model21.
NCAM2 contains a Walker A motif in the FnIII2 AB loop. However, the potential ATP-binding to this site and 
the potential interaction between the NCAM2 FnIII domains and FGFR has not been investigated.
This study presents a nuclear magnetic resonance (NMR) spectroscopy model of NCAM2 FnIII2. 
Supplementary titration experiments show that ATP does not bind the Walker A motif in the NCAM2 FnIII2 
domain. We show that the NCAM2 FnIII domains can induce neurite outgrowth through binding and activation 
of FGFR. Only 2 of 6 synthetic NCAM2-derived peptides stimulated neurite outgrowth, but at least 1 of these 
peptides seemed to work through binding and activation of FGFR.
Results
Expression and purification of recombinant proteins. To study the potential interaction between 
NCAM2 FnIII2 and ATP, a recombinant protein corresponding to the FnIII2 domain of human NCAM2 was 
expressed in the yeast Pichia pastoris. The domain was produced with a C-terminal His-tag, and had a total length 
of 108 amino acids. It was purified by affinity chromatography and gel filtration, and the purity was verified by 
SDS-PAGE (see Supplementary Fig. S1) and mass spectrometry (see Supplementary Fig. S2) before NMR spectra 
were obtained. Mass spectrometry showed that the final purified FnIII2 domain was heterogeneous with 2 or 
4 extra residues originating from the signal peptide, due to inefficient Ste13 cleavage in P. pastoris. In addition 
to the structural analysis, the recombinant protein expressed by P. pastoris was used for in vitro binding stud-
ies using SPR analysis. Moreover, recombinant NCAM2 FnIII1, FnIII2, and FnIII1-2 domains were expressed 
in E. coli. The folding of the protein expressed in E. coli was verified by circular dichroism (CD) experiments 
(see Supplementary Fig. S3), and the proteins were used for SPR analysis, small-angle X-ray scattering (SAXS) 
experiments, as well as for cell culture studies. The main reason for changing the expression system from yeast to 
bacteria was to lower cost and increase yield to be able to perform more advanced scattering experiments such as 
contrast variation using small angle neutron scattering in the future.
NMR structure determination and interaction studies. The NMR structure of the NCAM2 FnIII2 
domain was calculated from a total of 2073 structural restraints (see Supplementary Table S1) and has been 
deposited to the Protein Data Bank (PDB code 2kbg). The experimental details of the structure are given in 
Supplementary Information (Table S1, Figures S4, S5 and S6). Not surprisingly, the structure is highly simi-
lar to the X-ray structure (r.s.m.d. = 0.95 Å using backbone atoms I8-F91 of the NCAM2 FnIII2 NMR ensemble 
against the same domain determined in the context of a longer ectodomain construct (PDB code: 2jll)). When 
comparing the NMR structure with the X-ray structure it is evident that a loop (K42-D46) is missing in the X-ray 
structure. This loop is well characterized in the NMR structure, and has a significant influence on the SAXS anal-
ysis. However, the overall topologies of the NMR and X-ray structures are identical, with a β-sandwich formed 
by two anti-parallel β-sheets consisting of 3 and 4 β-strands, respectively. One β-sheet is composed of β-strands 
A (I8-S14), B (S17-I22), and E (H59-L62). The other β-sheet is composed of β-strands C’ (L49-Q54), C (L33-S41), F 
(Y71-A78), and G (T87-F91) (see Supplementary Fig. S4b).
The FnIII2 domain of NCAM2 is similar (r.m.s.d = 1.37 Å using same part of the NCAM2 FnIII2 ensem-
ble as above) to the corresponding FnIII2 domain from NCAM1 (PDB code: 1lwr). However, the locations 
of the Walker A motifs are different in the 2 domains (Fig. 1); in NCAM1 FnIII2 the motif is located in the 
membrane-distal FG loop (amino acid residues 77–84) whereas the motif in NCAM2 FnIII2 is located in the 
membrane-proximal AB loop (amino acid residues 10–17).
To determine if NCAM2 FnIII2 can bind AMP-PCP, a non-hydrolysable ATP-analogue, via the Walker 
A motif, we measured 15N-HSQC on free NCAM2 FnIII2 and on AMP-PCP saturated NCAM2 FnIII2. The 
small chemical shift differences (see Supplementary Fig. S6) revealed that AMP-PCP did not bind the Walker 
A motif, but interacted with residues K42-K44, D46-Q47, H64, Q66-W67, K96, N98 and I99. This suggests that the 
negatively-charged phosphate groups of AMP-PCP interacted with the charged residues K42-K44, D46, H64, K96, 
and that the adenosine moiety of AMP-PCP formed hydrophobic interactions with W67 and I99. When high-
lighted on the structure the binding surface appears at the membrane-proximal part of the FnIII2 domain, and 
not on the side of the domain where the Walker A motif is located (see Fig. 1). The results therefore suggest that 
the interaction is not biologically relevant.
Structural analysis of NCAM2 FnIII1-2 in solution. The X-ray structure of NCAM2 IgIV-FnIII2 (PDB 
code: 2jll) indicates a relatively static structure in the region of the FnIII domains due to the very short (two 
amino acid residues) linker between the FnIII1 and -2 domains. Notably, the linker contains a proline residue, 
which, due to its ring structure, is expected to rigidify the short linker. Moreover, the possibilities for hydrogen 
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bonds between the FnIII1 domain and the linker could further rigidify this part of NCAM2. To investigate the 
structure in more detail we performed SAXS experiments (Fig. 2a), which give information of the overall shape 
and flexibility of proteins in solution. NCAM2 FnIII1-2 Mw was determined with high precision to be within 6% 
of the theoretical Mw (Table 1), and no aggregation was observed from the Guinier region (see Supplementary 
Fig. S7a). A CRYSOL fitting using the NCAM2 FnIII1-2 domain models from a crystal structure (PDB code: 
2jll) including a model of the His-tag indeed corresponded to the measured NCAM2 FnIII1-2 SAXS data with a 
χ2-value of 0.86 (see Supplementary Fig. S7b). This indicates that the FnIII1-2 structure in solution indeed is rela-
tively rigid. Since the region between NCAM2 FnIII1 and -2 previously, in a simulation study, has been described 
as flexible17, and the Kratky plot derived from the SAXS data presented here showed multi-domain scattering par-
ticle with flexibility (Fig. 2b) we performed SREFLEX22 analysis on NCAM2 FnIII1-2. This algorithm estimates 
flexibility by allowing for conformational changes in order to improve agreement with experimental scattering 
curve. The normal mode analysis resulted in a better agreement with experimental data (Fig. 2a, χ2 = 0.81), but 
the flexibility was due the C-terminal region with the His-tag (Fig. 2c). This indicates that the linker between the 
FnIII domains in NCAM2 should be seen as a rigid linker, and could maintain the 2 FnIII domains at a prefixed 
position to enhance interactions with ligands, such as an NCAM2-FGFR interaction.
NCAM2 FnIII domains interact with FGFR1. Since NCAM1 FnIII domains have been shown to interact 
in vitro with FGFRs19,23, we tested whether human NCAM2 FnIII domains and FGFR1 could also interact in vitro.
Surface plasmon resonance (SPR) analysis demonstrated a concentration-dependent binding between 
FGFR1β immobilized on the chip, and NCAM2 FnIII domains in solution (Fig. 3). On the same chip an Ig 
domain had been immobilized as a negative control to detect unspecific binding. No unspecific binding was 
observed for any of the tested FnIII domains (Fig. 3). By steady state fitting we roughly estimated the Kd’s for 
the interactions between FGFR1β and the NCAM2 FnIII domains. The Kd’s were all in the µM range (Fig. 3), 
which corresponds to Kd values obtained for other FGFR-FnIII domains interactions23. Kd’s obtained from 
NCAM2 FnIII1-2 domains expressed from P. pastoris or in E.coli were in similar range 0.4 µM with χ2 = 0.061 
(Supplementary Fig. S8) and 0.13 µM with χ2 = 0.028 (Fig. 3), respectively. Thus, the Kd for what we see as the 
biologically binding partner to FGFR, was reproducible.
NCAM2 FnIII domains stimulate neurite outgrowth. To investigate the biological function of the 
NCAM2 FnIII domains, we investigated neurite outgrowth in response to exposure to the FnIII domains. Rat cer-
ebellar granule neurons (CGNs) were seeded on Permanox in the absence or presence of NCAM2 FnIII domains 
coated in different concentrations. As seen from micrographs in Fig. 4a–d FnIII1, FnIII2, and FnIII1-2 all induced 
Figure 1. The Walker A motif is located differently in NCAM1 and NCAM2. The figure shows the locations of 
the Walker A motif in the FnIII2 domains of NCAM1 ((a) PDB code: 1lwr) and NCAM2 ((b) PDB code: 2kbg). 
The domains are presented as surface models, and are oriented in a manner that enables the visualization of the 
Walker A motifs, which are located differently in the two proteins. Moreover, the domains are oriented with the 
membrane-proximal end facing down. FGL and ABL indicate the Walker A motif-containing loop regions of 
NCAM1 and NCAM2, respectively. The Walker A motifs and residues perturbed when titrating NCAM2 FnIII2 
with AMP-PCP are colored yellow and red, respectively.
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neurite outgrowth at a coating concentration of 4 µM, when compared to the negative control. Our negative 
control does not induce neurite outgrowth. Previous studies performed with BSA, also shows that it does not 
induce neurite outgrowth24. Figure 4e–g presents concentration-response curves of the average neurite lengths in 
response to different concentrations of the respective FnIII constructs. FnIII1, FnIII2, and FnIII1-2 all statistically 
significantly induced neurite outgrowth in a concentration-dependent manner. Surprisingly, no synergistic effect 
was observed for the combination of FnIII1 and -2. Thus, the single domains and the double domain construct 
induced neurite outgrowth with apparently similar potencies and efficacies (Fig. 4e–g).
To investigate the signaling pathway involved in the neurite outgrowth induced by the FnIII domains exper-
iments were performed, where neurite outgrowth induced by FnIII1-2 was estimated in response to treatment 
with different concentrations of an FGFR inhibitor (SU5402) and a MEK 1/2 inhibitor (U0126).
Figure 5a shows that SU5402 statistically significantly inhibited the neurite outgrowth induced by FnIII1-2 by 
~50% already at a concentration of 11 μM. However, higher concentrations of SU5402 had only minor additional 
inhibitory effects. These data suggest that neurite outgrowth induced by NCAM2 FnIII1-2 in part, but not exclu-
sively is mediated through activation of FGFR.
Figure 5b shows that U0126 statistically significantly inhibited the neurite outgrowth induced by FnIII1-2 in a 
concentration-dependent manner to a level not significantly different from the negative control (cell cultured in 
the absence of FnIII1-2 and U0126). These data indicate that the neurite outgrowth induced by NCAM2 FnIII1-2 
is mediated by signaling through the Ras-MAPK pathway. The total average neurite lengths in µm and standard 
error of means (SEMs) can be found in Supplementary Table S2.
Figure 2. Flexibility of the NCAM2 FnIII1-2 domains. SAXS scattering data (a) was plotted in a Kratky plot (b), 
and revealed a multi-domain protein with flexibility. Due to flexibility, normal mode analysis was performed 
with SREFLEX. This resulted in 3 structural models (c) restrained models [blue] and unrestrained model [grey]) 
representing possible conformational changes improving the fit to experimental SAXS profile (a). According to 
the SREFLEX analysis the flexibility is located C-terminally with the His-tag moving freely around.
Rga (nm) Rgb (nm) Vpc (nm3) MwExpd (kDa) MwExpe (kDa) Mwf (kDa)
NCAM2FnII1-2 3.18 3.31 32.96 23.48 23.64 22.43
BSA 3.08 3.14 117.80 67.32 67.67 66.46
Table 1. Data from SAXS analysis of NCAM2 FnIII1-2 and bovine serum albumin (BSA). aRadius of gyration, 
Rg, estimated from the Guinier approximation. bRg estimated by AutoGNOM. cThe excluded hydrated volume 
(Porod volume), Vp. dMolecular weight, Mw, estimated from I(0) obtained by the Guinier approximation. eMw 
estimated from AutoGNOM. fTheoretical Mw.
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Figure 3. NCAM2 FnIII domains bind to FGFR1. Surface plasmon resonance analysis was utilized to 
investigate interactions between the NCAM2 FnIII1, FnIII2, and FnIII1-2 domains and the ectodomain of 
FGFR1. Approximately 1000 resonance units (RUs) of the FGFR1β ectodomain (Ig2-Ig3) were immobilized 
on a sensor chip and recombinant NCAM2 FnIII1 (a), FnIII2 (b) and FnIII1-2 (c) were injected at the 
indicated concentrations. Binding is expressed as the response difference between the binding of the respective 
recombinant proteins to a cell on the sensor chip with the immobilized FGFR1β and a control cell on the same 
sensor chip coated with IgG (d). On the basis of the presented steady state affinity fit curves, Kd values of 0.29 
(χ2 = 0.057), 4.4 (χ2 = 0.016) and 0.13 (χ2 = 0.028) μM were estimated for NCAM2 FnIII1 (d), FnIII2 (e) and 
FnIII1-2 (f), respectively.
Figure 4. NCAM2 FnIII1, FnIII2 and FnIII1-2 domains induce neurite outgrowth. CGNs were grown for 24 h 
on a coat of different concentrations of recombinant NCAM2FnIII-domains. The neurons were immunostained 
and neurite lengths were estimated by a stereological approach from the recorded micrographs. Top panel: 
Representative micrographs showing CGNs grown on 0 μM protein (control, a), and 4 μM NCAM2 FnIII1 (b), 
FnIII2 (c), and FnIII1-2 (d), respectively. (e–g) Concentration-response curves for normalized average neurite 
length vs. concentration of NCAM2 FnIII1 (e), NCAM2 FnIII2 (f), and NCAM2 FnIII1-2 (g), respectively. 
Before cells were plated the wells were coated with 7 concentrations of the respective NCAM2 FnIII domains  
(0, 0.3125, 0.625, 1.25, 2.5, 5.0, 10.0 µg/cm2). Data have been normalized to the negative control (0 μM protein) 
and are shown as mean and SEM (n = 3–4). The individual concentration-response data were analyzed 
separately by one-way ANOVA for repeated measures followed by Tukey’s multiple comparison test. All 3 
proteins significantly induced neurite outgrowth. NCAM2 FnIII1: F (6, 21) = 3.472, p < 0.0153. NCAM2 FnIII2: 
F (6, 12) = 18.72, p < 0.0001. NCAM2 FnIII1-2: F (6, 12) = 13.94, p < 0.0001. *,** and ***p < 0.05, 0.01, and 
0.001, respectively, when compared to the negative control. Scale bars = 10 µM. The total average neurite length 
per cell for domains can be found in Supplementary Table S2.
www.nature.com/scientificreports/
6SCieNtiFiC RepoRTs |  (2018) 8:8957  | DOI:10.1038/s41598-018-27089-7
Sequence-based investigations for an NCAM2 FnIII1-2-FGFR interaction site. Since the FnIII1-2 
domains bind FGFR (Fig. 3) and in part stimulate neurite outgrowth by activation of FGFR (Fig. 5a) we tried to 
identify regions of high sequence conservation between NCAM1 FnIII1-2, and NCAM2 FnIII1-2. In particular, 
we focused on the sequences of synthetic peptides derived from NCAM1 reported to stimulate neurite outgrowth 
through binding and activation of FGFR. In the literature 5 NCAM1 peptides (EncaminA (FnIII1), EncaminC 
(FnIII1), EncaminE (FnIII1), BCL (FnIII2), and FGL (FnIII2) are reported to bind and activate FGFR19,25,26. Each 
peptide corresponds to a structural motif consisting of 2 adjacent β-strands and the loop between them, as high-
lighted in green on the structure of NCAM1 FnIII1-227 shown in Fig. 6a, and the sequence alignment in Fig. S9. 
From the sequence alignments, it is evident that 4 out of the 5 NCAM1-derived peptides (EncaminA, EncaminC, 
EncaminE and BCL) are conserved between human NCAM1 and NCAM2 in the loop regions with respect to 
amino acids properties such as hydrophobicity, polarity, and charge (see Supplementary Fig. S9).
The sequences corresponding to the Encamin peptides are 23–35% conserved between the 2 proteins. 
The BCL peptide (NLIKQDDGGSPIRHY) derived from the NCAM1 FnIII2 domain is the peptide where the 
sequence is most highly conserved between NCAM1 and NCAM2 FnIII2 domains (60%), and this sequence 
is also highly conserved across the selected species. The glutamine residue in position 5 of BCL is essential 
for the function of the peptide. Thus, a Q → A substitution completely abrogates the function of the peptide26. 
Interestingly, this glutamine residue is conserved between NCAM1 and -2. The least conserved loop region 
between NCAM1 and NCAM2 FnIII2 domains (40%) is found in the sequences corresponding to the FGL pep-
tide (EVYVVAENQQGKSKA). Substitution of the 2 glutamine residues (polar uncharged) at positions 9–10 to 
alanine residues totally abrogates the neuritogenic effect of FGL19. In the corresponding region of NCAM2 FnIII2 
the 2 glutamine residues are replaced with an arginine residue (charged) and a leucine residue (hydrophobic) (see 
Supplementary Fig. S9).
Synthetic peptides derived from NCAM2 FnIII1 and FnIII2 activate FGFR. Based on the sequence 
analysis described above we designed peptides derived from sequences in the NCAM2 FnIII1-2 domains, but 
corresponding to NCAM1 EncaminA, -C and -E (peptides derived from the FnIII1 domain, denoted FnIII1-AB, 
FnIII1-CD and FnIII1-EF), BCL and FGL (derived from the FnIII2 domain, denoted FnIII2-BC and FnIII2-FG 
respectively). We also designed a peptide from the FnIII2 AB loop (FnIII2-AB), since this region contains the 
potential Walker A motif. Like the NCAM1-derived peptides, the NCAM2-derived peptides were synthesized as 
tetramers linked to a lysine backbone, thus enabling clustering of potential binding partners.
The biological activities of the designed peptides were tested by performing concentration-response evalua-
tions of their abilities to stimulate neurite outgrowth in primary cultures of CGNs (Fig. 7). Only 1 peptide from 
the FnIII1 domain, FnIII1-AB, corresponding to EncaminA in NCAM1, had significant effects on neurite out-
growth. This peptide demonstrated a statistically significant bell-shaped, concentration-dependent stimulation 
of neurite outgrowth with a maximal stimulation of ~600% at a concentration of 1.3 μM (Fig. 7d). Additional 
peptides derived from the FnIII1 domain, FnIII1-CD and FnIII1-EF, corresponding to EncaminC and -E from 
NCAM1, had no significant effects on neurite outgrowth within the tested concentration ranges (Fig. 7e,f).
Figure 5. NCAM2 FnIII1-2 activates signaling through FGFR and MEK. CGNs were treated for 24 h with 
different concentrations of the FGFR kinase inhibitor SU5402 (Sigma Aldrich; a) or the MEK inhibitor U0126 
(MERCK; b) in the absence (black curves) or presence (blue curves) of 4 μM NCAM2 FnIII1-2. The inhibitors 
were added to the wells 10 min after the cells had been plated. In each experiment, 4 concentrations were used 
per inhibitor: 0, 11.1, 33.3 and 100 μM (for SU5402), and 0, 2.2, 6.6 and 20 μM (for U0126). Average neurite 
lengths were estimated by a stereological approach from recorded micrographs. Data are shown normalized to 
control (0 μM inhibitor in the absence of FnIII1-2) as mean and SEM (n = 3). The individual concentration-
response data were analyzed by one-way ANOVA for repeated measures followed by Tukey’s multiple 
comparison test. (a) F (12, 35) = 36.55, p < 0.0001. (b) F (12, 35) = 28.14, p < 0.0001. *,** and ***p < 0.05, 0.01, 
and 0.001, respectively, when compared to negative control (no FnIII1-2, 0 μM inhibitor). +,++ and +++p < 0.05, 
0.01, and 0.001, respectively, when compared to positive control (FnIII1-2, 0 μM inhibitor). The effect of 
the total average neurite length per cell for domains cultured with inhibitor can be found in Supplementary 
Table S2.
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Of the 3 peptides derived from NCAM2 FnIII2 only 1 peptide, FnIII2-BC (corresponding to the BCL peptide 
from NCAM1), had moderate, but significant effects on neurite outgrowth. This peptide induced a statistically 
significant, bell-shaped, concentration-dependent stimulation of neurite outgrowth with a maximal stimulation 
of ~200% at a concentration of 1.3 μM (Fig. 7h). The 2 peptides FnIII2-AB (containing the Walker A motif) and 
FnIII2-FG (corresponding to the FGL peptide derived from NCAM1) had no statistically significant effects on 
neurite outgrowth within the tested concentration ranges (Fig. 7g,i). FnIII2-BC unfortunately demonstrated a 
high degree of variability in the biological effects, and consequently it was necessary to exclude this peptide from 
further investigations. However, since FnIII1-AB represented a potential FGFR binding site in NCAM2, it was 
decided to investigate whether the neuritogenic effect of this peptide was mediated through FGFR.
Dendrimeric FnIII1-AB induces neurite outgrowth through FGFR and MEK1/2. Experiments were 
conducted, where CGNs grown in the absence or presence of FnIII1-AB were stimulated with different concen-
trations of the FGFR kinase inhibitor SU5402 or the MEK1/2 kinase inhibitor U0126.
The dose-response data for the experiments with the 2 inhibitors are shown in Fig. 8. Already at a concen-
tration of 11 μM SU5402 inhibited FnIII1-AB-induced neurite outgrowth by more than 50% (Fig. 8a). However, 
higher concentrations of SU5402 did not inhibit the response further. Dose-response experiments with U0126 
demonstrated that the neurite outgrowth-stimulating effect of FnIII1-AB could be almost entirely inhibited even 
at low concentrations of the inhibitor (Fig. 8b).
These results suggest that FnIII1-AB to a large extent, but not exclusively, stimulated neurite outgrowth 
through activation of FGFR, and that the response requires activation of the Ras-MAPK pathway. The total aver-
age neurite lengths in µm and SEMs can be found in Supplementary Table S3.
Figure 6. Structural comparison of the NCAM1 and NCAM2 FnIII domains. The FnIII domains (grey) from 
NCAM1 ((a) PDB code: 2vkw) and NCAM2 ((b) PDB code: 2jll) were aligned to compare secondary structure 
differences. The domains are oriented with the membrane-proximal end facing down. Pairwise, the domains 
have same overall topology. However, NCAM1 FnIII1 contains an α helix between the D and E strands not 
observed in NCAM2 FnIII1. Biologically active peptides derived from NCAM1 FnIII1-2 (EncaminA, -C, -E, 
BCL and FGL) are colored in green. All NCAM1 FnIII1-2 peptides are in the literature reported to interact 
with FGFR53. Peptides derived from NCAM2 FnIII1-2, and used in this study are colored red (biologically 
active, ABL and BCL) and blue (not biologically active). When comparing the regions of NCAM1, from which 
the respective peptides are derived, with the corresponding regions in NCAM2, they all have highly identical 
secondary structures.
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Figure 7. Neurite outgrowth induced by synthetic peptides derived from NCAM2 FnIII1 and FnIII2. 
CGNs were treated with dendrimeric peptides at the indicated concentrations for 24 h. The neurons were 
immunostained and average neurite lengths were estimated by a stereological approach from recorded 
micrographs. Top panel shows representative micrographs of CGNs: not stimulated (control) (a), stimulated 
with NCAM2-FnIII1-AB (b), and NCAM2-FnIII2-BC (c). Graphs d-f show data for peptides derived from 
sequences in NCAM2 FnIII1, and graphs g-i show data for peptides derived from sequences in NCAM2 
FnIII2. The graphs present concentration-response curves for average neurite length vs. the concentration of 
the respective peptides. Data were normalized to the negative control (0 μM peptide) and are shown as mean 
and SEM (n = 3). The individual concentration-response data were analyzed by one-way ANOVA for repeated 
measures followed by Tukey’s multiple comparison test. FnIII1-AB: F (6, 12) = 20.45, P < 0.0001. FnIII1-CD: F 
(6, 12) = 1.056, P = 0.4384. FnIII1-EF: F (6, 6) = 0.6812, P = 0.6736. FnIII2-AB: F (6, 12) = 0.5348, P = 0.7723. 
FnIII2-BC: F (6, 12) = 3.944, P = 0.0207. FnIII2-FG: F (6, 12) = 2.844, P = 0.0583. *,** and ***p < 0.05, 0.01, 
and 0.001, respectively, when compared to control. Scale bars = 10 µm. The total average neurite length per cell 
for peptides can be found in Supplementary Table S3.
Figure 8. Dendrimeric FnIII1-AB induce neurite outgrowth through FGFR and MEK1/2. CGNs were treated 
for 24 h with different concentrations of the FGFR kinase inhibitor SU5402 (a) or the MEK inhibitor U0126 (b) 
in the absence (black curves) or presence (blue curves) of 3.9 μM dendrimeric FnIII1ab. Average neurite lengths 
were estimated by a stereological approach from recorded micrographs. Data were normalized to the negative 
control (0 μM inhibitor in the absence of peptide) and are shown as mean and SEM (n = 2). The effect of the total 
average neurite length per cell for FnIII1-AB cultured with inhibitor can be found in Supplementary Table S3.
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Discussion
Walker A motifs are associated with phosphate binding, and have the general pattern A/G-XXXX-GK-S/T with X 
being an arbitrary amino acid residue. Especially the lysine residue and the main chain are crucial for nucleotide 
binding28. The motif is present in many ATP and GTP utilizing proteins such as ATP synthase and myosin, but 
is also found e.g. in NCAM1, where binding of ecto-ATP to the motif abrogates NCAM1-FGFR interactions19,29. 
Using NMR we here show that the Walker A motif in the NCAM2 FnIII2 domain does not bind the ATP analogue 
AMP-PCP (Fig. S6).
In NCAM1 FnIII2 the motif is located in the distal part of the domain, whereas it in NCAM2 FnIII2 is located 
close to the membrane (Fig. 1). The fact that both proteins do have a Walker A motif is therefore not the result 
of sequence homology, and therefore it is not surprising, that the functions of the Walker A motifs in the two 
proteins are not conserved. The interaction between NCAM1 and the ATP analogue involves two lysine residues 
and a tyrosine residue, and it has been hypothesized that the adenine ring of ATP makes π-π stacking with the 
aromatic tyrosine ring, while the negatively charged phosphate groups interact with the two positively charged 
lysine side-chains in at ‘fork’-like manner19. It is clear, when comparing the two primary structures, that NCAM2 
lacks an extra lysine and an aromatic residue. Therefore, it seems likely that these residues are crucial to the inter-
action, and could be the reason for the lack of NCAM2 AMP-PCP interaction at the Walker A motif. Indeed the 
Walker A motif in NCAM2 may have no function, since a synthetic peptide derived from this region of NCAM2 
also failed to demonstrate any biological activity (Fig. 7d).
The primary structure of the FnIII2 FG loop is poorly conserved between NCAM1 and NCAM2, whereas 
the tertiary structures are very similar as seen from the alignment of NCAM1- and NCAM2 FnIII2 (Fig. 6). In 
NCAM1 the FnIII2 FG region is important both for ATP binding and NCAM1-FGFR interactions19, whereas this 
is not the case for NCAM2, where a synthetic peptide derived from this region demonstrated no biological activ-
ity (Fig. 7f). Hence, it is the specific sequence or the amino acid composition of the NCAM1 FnIII2 FG loop, and 
not its position relative to the membrane or its tertiary structure, that is important for its ability to bind FGFR. 
Consistent with this interpretation, two amino acid residues (QQ) vital for the binding of this region of NCAM1 
to FGFR19 are missing in NCAM2.
The functional differences between the FnIII domains of NCAM1 and NCAM2 are supported by SPR analyses 
and biological studies. Thus, the Kd values for the binding of the FnIII1-2 domains of NCAM1 and NCAM2 to 
the Ig2-3 domains of FGFR1 are in the order of 10 µM19 and 0.13 µM (Fig. 3), respectively. In neurite outgrowth 
experiments, recombinant NCAM2 FnIII2 has prominently stronger effects on average neurite outgrowth than 
recombinant NCAM1 FnIII2. Thus, the NCAM1 domain could only stimulate neurite outgrowth of CGNs to 
an average neurite length of ~165% of the negative control19, whereas the NCAM2 domain stimulated neurite 
outgrowth to an average neurite length of ~300% of the negative control (Fig. 4). These differences should not be 
over interpreted, but an ability of NCAM2 to bind FGFR more strongly than NCAM1 would be a way to com-
pensate for the generally higher number of NCAM1 molecules in neurons (according to www.genecards.org30 the 
estimated level of NCAM1 protein in the nervous system is in the order of 10 times higher than that of NCAM2).
Inspecting the structural model of the NCAM2 ectodomain17, a different interaction mechanism between 
FGFR and FnIII1-2 domains of NCAM1 and NCAM2 makes sense, since a glycosylation site located in NCAM2 
FnIII1 (but not in NCAM1 FnIII1) might causes steric hindrance for an interaction between the NCAM2 FnIII2 
FG loop and FGFR by covering the FG loop17.
The observed rigidity of the NCAM2 FnIII1-2 double domain could be a way to predefine the distance for an 
NCAM2 trans-interaction and hence the cell-cell distance in NCAM2-mediated cell adhesion. It could also be a 
way to facilitate NCAM2-FGFR interactions, by making the NCAM2 FnIII1 domain easily accessible to FGFR.
Synthetic peptides were designed to map interaction sites between the NCAM2 FnIII domains and FGFR1. 
From the experiments we identified 2 peptides, which could induce neurite outgrowth, one from the FnIII1 
domain and one from the FnIII2 domain. The peptide from FnIII1 was more potent than the peptide from FnIII2 
(Fig. 7). This difference correlates with the measured Kd affinities for the binding of the respective FnIII domains 
to FGFR1 (0.29 µM and 4.4 µM; Fig. 3) and further supports the notion that a different interaction mechanism 
exists for the respective binding of NCAM1 and NCAM2 to FGFR. However, it should be emphasized that the 
NCAM2-derived peptides tested in this study do not cover all regions of the NCAM2 FnIII domains. Additional 
FGFR binding sites with potentially higher affinities may exist in the NCAM2 FnIII domains.
The peptide studies indicate that NCAM2 in part binds FGFR via the AB loop in FnIII1, and to a lesser extent 
via the BC loop in FnIII2, an observation that makes sense, since these regions spatially are in close proximity to 
each other (Fig. 6b).
In conclusion, the data demonstrate that ecto-ATP does not bind NCAM2 FnIII2, but that the NCAM2 FnIII 
domains do bind and activate FGFR. The function of the NCAM2-FGFR interaction in vivo should be investi-
gated in future studies.
Materials and Methods
Protein expression and purification. Recombinant human NCAM2 FnIII1 and FnIII1-2 (amino acid 
residues 498–591 and 498–693, respectively; UniProtKB identifier: O15394) were expressed in E. coli and refolded 
and purified using the strategy previously described31. Eluted proteins were further purified by size exclusion 
chromatography as described below; with the exception that pH was 7.4. For NMR the recombinant NCAM2 
FnIII2 (amino acid residues 592–693; UniProtKB identifier: O15394), here numbered amino acid residues 1–102, 
was expressed in the yeast P. pastoris16. The protein contained an N-terminal sequence (EAEASM), derived from 
the multiple cloning site of the pPICZaC vector (Invitrogen), and a C-terminal 6xHis-tag. The FnIII2 encod-
ing vector was transformed into the KM71H strain and expressed according to the manufacturer’s instruc-
tions (Invitrogen). The recombinant protein was purified by affinity chromatography using a Ni2+-NTA resin 
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(QIAGEN) followed by gel filtration using a HiLoad 16/60 XK 16 Superdex-75 prep grad column (GE Healthcare) 
and elution in an NMR buffer containing 20 mM Na2PO4/NaH2PO4 buffer, pH 6.5.
NMR measurements. The following samples were used to record NMR spectra: 1.4 mM uniform 
13C15N-labeled NCAM2 FnIII2 expressed from P. pastoris using 13C-methanol as carbon source (solubilized in 
H2O or D2O). For the assignment of the backbone atoms the following NMR spectra were recorded; 15N-HSQC 
in H2O or D2O, HNCACB, CBCA(CO)NH, HNCO, HN(CA)CO, HNCA and HN(CO)CA. To obtain side chain 
assignments the following additional spectra were recorded: CCONH, HCCONH, 15N-TOCSY-HSQC (50 ms), 
and HCCH-TOCSY (14 ms) for aliphatic and aromatic regions. The NOEs were obtained from the following 
NOESY spectra: 15N-NOESY-HSQC (150 ms) in H2O and 13C-NOESY-HSQC (100 ms) in D2O for aliphatic and 
aromatic regions. All spectra were recorded using the standard setup provided by the ProteinPack (Varian Inc.). 
The spectra were processed by the NMRPipe program32 and analyzed by the Ccpnmr program package33. The 
NMR experiments were all performed using either Varian Unity Inova 750 or 800 MHz spectrometer at 298 K.
Structure calculations. The initial structural model and automatic NOE assignments were performed using 
the CYANA.2.1 programme34. The automatic NOE assignment tolerance was set at 0.025-, 0.025- and 0.45 ppm 
for indirect 1H-, direct 1H-, and 13C or 15N dimensions, respectively. The upper limit values were set to 2.4–6.0 Å. 
Random seed was set to 434726. Subsequently, the 3D de novo structure model was recalculated for refinement 
using a simulated annealing protocol using the XPLOR-NIH program35,36. A total of 1934 NOE restrains were 
derived from the 100 ms 13C-NOESY-HSQC and the 150 ms 15N-NOESY-HSQC using the same upper limits 
(increased by 0.5 Å if needed). From the TALOS Programme37 59 additional torsion angle constrains were deter-
mined and applied to the structure calculation. In addition, 21 hydrogen bonds were estimated using MOLMOL38 
with the criteria that each H bond is located in all 20 structure models, and has a maximum distance of 2.4 Å 
with a 35° angle. The rate of hydrogen exchange for each amide was quantified by measuring 15N-HSQC spectra 
at t = 0 min, 60 min, and 24 h. after dissolving 1.4 mM NCAM2 FnIII2 in D2O to verify the presence of hydrogen 
bonds, which were included as restraints in the structure calculations. The structural model was calculated using 
Xplor-NIH and analyzed and checked using the MOLMOL and PROCHECK_NMR programs39. Figures were 
prepared using MOLMOL or PyMOL (http://www.pymol.org).
Small angle X-ray scattering (SAXS) data collection, processing and modelling. SAXS data 
of NCAM2 FnIII1-2 were collected at station BM29 at the European Synchrotron Radiation Facility Grenoble, 
France, using a PILATUS detector. Data were collected using a sample to detector distance of 2.87 m and a tem-
perature of 277.15 K covering a range of momentum transfer of 0.05 < s < 5 nm−1, where s = 4πsinθ/λ, 2θ is the 
scattering angle and λ = 0.992 Å. Absolute intensity calibration was carried out using water. Protein concentra-
tions were determined by measuring absorbance at 280 nm accounting for the theoretical extinction coefficient 
(29910 M−1 cm−1) calculated by the ProtParam40 algorithm at www.expasy.org. The concentration determination 
was based on an average of 3 measurements.
Data processing steps as background subtraction, scaling and merging were performed using the program 
PRIMUS41. The forward scatter, I(0), and the radius of gyration, Rg, were obtained using the Guinier approxima-
tion42 or from the entire scattering profile using AUTOGNOM43. AUTOGNOM also provided the pair distri-
bution function of the particle, P(r), and the maximum particle dimension, Dmax. The molecular mass (Mw) was 
estimated from the Guinier approximation and was crosschecked by calculating the excluded volume (Vp) of the 
hydrated particle from the Porod equation in AUTOPOROD43. Twenty ab initio models were reconstructed using 
GASBOR22i44 with default. The reconstructed models were aligned with SUPCOMB2045 and an average ab initio 
model was calculated by DAMAVER46. DAMFILT was used to represent the average ab initio model as a more 
compact and probable model by removing low occupancy and loosely connected dummy residues. CRYSOL47 
was used to calculate theoretical scattering curves high-resolution X-ray structure of NCAM2 FnIII1-2 with and 
without His-tag. The His-tag was manually added in PyMOL. SREFLEX22 in default mode was used to estimate 
the flexibility of the NCAM2 FnIII1-2 protein.
NCAM2 FnIII2 interaction with AMP-PCP. 13C15N-NCAM2 FnIII2 was titrated with AMP-PCP, a sta-
ble ATP analogue (Sigma). From the same protein stock 2 samples were prepared: A 1 mM free form sample of 
FnIII2, and a 1 mM saturated form sample including 5 mM AMP-PCP. All 15N-HSQCs were recorded on a Varian 
800 MHz spectrometer with cold probe at 298 K.
Circular dichroism analysis of refolded FnIII domains. The far-UV CD measurements were performed 
using a Jasco J-815 spectropolarimeter at 20 °C in a 1 mm path length quartz cuvette from Hellma over the wave-
length range 200–260 nm. A bandwidth of 1 nm and a scan speed of 20 nm/min were employed. At least 3 con-
secutive scans were obtained. The resulting data was smoothed and the contribution of the buffer blank was 
subtracted. The monitored scans were averaged.
Surface plasmon resonance (SPR) analysis. Binding studies between NCAM2 FnIII domains and 
FGFR1 were conducted on a BIAcore 2000 (GE Healthcare) at 25 °C using 10 mM PBS (pH 7.4) as a running 
buffer. Approximately 1000 RU FGFR1β (IIIc)/Fc chimera (R&D Systems, Minneapolis, MN, USA) and 750 RU 
recombinant human IgG1 Fc (Cat. No. 110-HG, carrier-free; R&D Systems) were immobilized on a CM4 sensor 
chip via an amine coupling kit (BIAcore) using a flow rate of 5 μl/min. The NCAM2 domains (PBS, pH 7.4) were 
injected at flow rate of 20–30 μl/min. The binding curves were analyzed using the BIAevaluation version 4.1 soft-
ware. A steady state affinity analysis was used to estimate Kd.
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Synthetic peptides. Synthetic peptides derived from the sequence of the human NCAM2 FnIII1 domain included 
FnIII1-AB (AGVKIIELSQTTAKVS), FnIII1-CD (VDVKEVASEIWKI), and FnIII1-EF (ANNLEPNTTYEIKV). 
Synthetic peptides derived from the sequence of the human NCAM2 FnIII2 domain included FnIII2-AB (GQPSSGKS), 
FnIII2-BC (SITKQDDGGAPILEY), and FnIII2-FG (EVQITAANRLGYSEPT). All peptides were produced as den-
drimers consisting of 4 monomers linked by a lysine backbone as described previously48 (Schafer-N A/S, Copenhagen, 
Denmark).
Primary cultures of rat cerebellar granular neurons. Cerebellar granule neurons (CGNs) were pre-
pared from 7–8 days-old Wistar rats (Charles River) as previously described49. CGNs were plated in 8-well 
uncoated Permanox® LabTek® Chamber Slides™ (Nunc®) at a density of 50.000 cells/well in Neurobasal A 
medium with 0.5% (v/v) Glutamax, 2% (v/v) B27 and 4 mg/ml bovine serum albumin (Invitrogen). The cells were 
cultured at 37 °C, 5% CO2 in a humidified atmosphere for 24 h before they were prepared for immunofluorescence 
microscopy.
No animal experiments were performed. Rats were treated in accordance with the Danish Animal Protection 
Act and were euthanized prior to the preparation of primary cell cultures.
Immunofluorescence staining for GAP-43. CGNs were fixated in 4% (v/v) formalin, 1% methanol in 
PBS and immunostained with polyclonal rabbit antibodies directed against the neuron-specific protein GAP-43 
(1:1000; Chemicon). The GAP-43 staining was visualized using Alexa Fluor® 488-conjugated secondary antibod-
ies (1:1000; Invitrogen).
Neurite outgrowth analysis. Micrographs of GAP-43-stained neurons were recorded using an inverted 
Zeiss Axiovert 100 microscope equipped with a 20x, 0.75 NA objective and coupled to a Zeiss, AxiocamMRm 
video camera (Carl Zeiss A/S, Birkeroed, Denmark). The average length of processes per neuron was estimated 
using a stereological approach as described50. For each well, 150–200 neurons were captured and analyzed.
Sequence alignment analysis. Sequences of NCAM1- and NCAM2 FnIII1-2 from Homo sapiens 
(UniProtKB identifier P13591 and O15394), Rattus norvegicus (UniProtKB identifier P13596 and A0A0G2K7P9), 
and Mus musculus (UniProtKB identifier P13595 and O35136) were obtained from uniprot.org, and aligned using 
MUSCLE51,52 with default setting in Jailview (2.10.1). Sequences used can be found in SI (Table S4).
Data availability. All data generated or analysed during this study are included in this published article (and 
its Supplementary Information files).
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